ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Jan. 31, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers of shares of PixarBio Corp (PXRB) over alleged Securities Laws Violations by PixarBio Corp.
Investors, who purchased shares of PixarBio Corp (OTCMKTS:PXRB) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016 and/or publicly traded on the open market from October 31, 2016 through January 20, 2017, have certain options and for certain investors there are short and strict deadlines running. Deadline: March 27, 2017. OTCMKTS: PXRB investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose that the market for PixarBio’s securities exhibited manipulative or deceptive activities, that PixarBio’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and PixarBio’s current and prospective development efforts lacked veracity, and that as a result, defendants’ public statements were materially false and misleading at all relevant times.
On January 23, 2017, the Securities and Exchange Commission (“SEC”) announced the temporary suspension of trading in the securities of PixarBio Corp (OTCMKTS:PXRB) “because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the company’s current and prospective development efforts.”
Those who purchased PixarBio Corp (OTCMKTS:PXRB) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
